Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2 mutated/amplified metastatic solid tumors
NCT05274191Phase 2Unknown
- Sponsor
- Xiamen University Zhongshan Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib in non-small cell lung cancer (NSCLC), gastric adenocarcinoma, colorectal adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Xiamen University Zhongshan Hospital. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinomacolorectal adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05274191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274191.